News headlines about Assembly Biosciences (NASDAQ:ASMB) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Assembly Biosciences earned a news impact score of 0.19 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.2327370394142 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Assembly Biosciences (NASDAQ:ASMB) opened at $58.17 on Friday. Assembly Biosciences has a twelve month low of $18.60 and a twelve month high of $67.36. The firm has a market capitalization of $1,178.02, a price-to-earnings ratio of -19.59 and a beta of 0.57.
A number of research analysts recently weighed in on the company. BidaskClub lowered Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday. ValuEngine raised Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. Jefferies Group upped their price objective on Assembly Biosciences to $75.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. Zacks Investment Research lowered Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 14th. Finally, B. Riley assumed coverage on Assembly Biosciences in a report on Friday, January 5th. They set a “neutral” rating and a $35.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Assembly Biosciences currently has a consensus rating of “Buy” and a consensus target price of $54.25.
In related news, Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $46.86, for a total transaction of $46,860.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold 3,000 shares of company stock worth $148,270 in the last ninety days. 19.60% of the stock is currently owned by corporate insiders.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.